A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT #
NCT05519449
Condition(s)
Prostate Cancer
Molecular Target(s)
CD3, PSMA
Drug Classification(s)
Targeted Immunotherapy
Agents(s)
JANX007
Phase(s)
I
Mechanism of Action
JANX007 is a Tumor Activated T Cell Engager therapuetic targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- How the level of certain molecules (biomarkers) in your blood changes over time while receiving the study agent
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.